THE NEW ENGLAND JOURNAL OF MEDICINE

Boston, MA 02215

Oct. 9, 1986




Figure 1. Interstitial Cardiac Mast Cell (Patient 1 [×4700]), with Extruded, Membrane-Free Granules with Altered Matrix (Arrows). Some granules are in the process of being released from this undamaged mast cell. All cytoplasmic granules also show swelling, altered matrix, fusions of granule membranes, and formation of intracytoplasmic degranulation channels. Dense lipid bodies are unaltered (open arrows).

left and right ventricles and a decreased left ventricular ejection fraction.

Anaphylactic degranulation of human mast cells has been studied in isolated mast cells from the lungs.^{7,8} These studies have shown degranulation channel formation and intracytoplasmic altered granule matrices, which ultimately dissolve before opening of channels to the cells' exterior. Rarely, extrusion of altered, nonmembrane-bound granules through plasma-membrane openings was also seen. Images diagnostic of anaphylactic degranulation of human mast cells in vivo are extremely rare. They must be extremely rapid events, and have been recorded with certainty only in skin specimens stimulated either by scratching a lesion of urticaria pigmentosa⁹ or by intradermal injection of C5a.¹⁰ In both instances, actual granule extrusion was recorded.

We present these two cases to document the unequivocal occurrence of degranulation of mast cells in human heart tissues in vivo. The degranulation mechanism includes the extrusion of altered, membrane-free granules to the cells' exterior, as well as intracytoplasmic solubilization of granules and degranulation channel formation. Although these are difficult images to capture in vivo, in vitro studies with isolated human pulmonary mast cells clearly asso-




Figure 2. Interstitial Cardiac Mast Cell (Patient 2 [×8550]), with Extrusion of Membrane-Free, Swollen Granules with Altered Matrix Patterns from Multiple Openings in the Plasma Membrane (Arrows). Many typical cytoplasmic granules show no alterations

Many typical cytoplasmic granules show no alteration: (open arrow). ciate these morphologic events with the rapid release of histamine.^{7,8} Although the precise triggering mechanism, among the many possible ones, cannot be determined by morphologic analysis alone, the identification of these morphologic events suggests a role for mast cells and their release reactions in the pathogenesis of otherwise unexplained cardiac disorders.

> ANN M. DVORAK, M.D. Beth Israel Hospital

- Estensen RD. Eosinophilic myocarditis: a role for mast cells? Arch Pathol Lab Med 1984; 108:358-9.
- Triggiani M, Genovese A, Vigorito C, Marone G. Histamine and human heart. Int Arch Allergy Appl Immunol 1985; 77:174-6.
- Levi R, Wolff A, Robertson DA, Graver LM. IgE-mediated hypersensitivity and ischemia as causes of endogenous cardiac histamine release. Adv Biosci 1985; 51:305-8.
- Kalsner S, Richards R. Coronary arteries of cardiac patients are hyperreactive and contain stores of amines: a mechanism for coronary spasm. Science 1984; 223:1435-7.
- Ginsburg R, Bristow MR, Kantrowitz N, Baim DS, Harrison DC. Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris. Am Heart J 1981; 102:819-22.
- Michelassi F, Landa L, Hill RD, et al. Leukotriene D₄: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction. Science 1982; 217:841-3.
- Dvorak AM, Hammel I, Schulman ES, et al. Differences in the behavior of cytoplasmic granules and lipid bodies during human lung mast cell degranulation. J Cell Biol 1984; 99:1678-87.
- Dvorak AM, Schulman ES, Peters SP, et al. Immunoglobulin E-mediated degranulation of isolated human lung mast cells. Lab Invest 1985; 53:45-56.
- Kobayasi T, Asboe-Hansen G. Degranulation and regranulation of human mast cells: an electron microscopic study of the whealing reaction in urticaria pigmentosa. Acta Derm Venereol (Stockh) 1969; 49:369-81.
- Yancey KB, Hammer CH, Harvath L, Renfer L, Frank MM, Lawley TJ. Studies of human C5a as a mediator of inflammation in normal human skin. J Clin Invest 1985; 75:486-95.

ENTERIC HYPEROXALURIA AND UROLITHIASIS

To the Editor: Patients with small intestinal disease, jejunoileal bypass, or ileal resection may have hyperoxaluria and calcium oxalate urolithiasis as a complication.¹⁻³ The cause of the hyperoxaluria, has now been shown to be hyperabsorption of oxalate from the bowel due to complexing of calcium by the malabsorbed fatty acids in the gut⁴ and increased colonic permeability to oxalate caused by both bile and fatty acids.⁵

Recently we showed that patients with recurrent calcium-stone formation had malabsorption of ascorbate from the gut, which in turn resulted in increased conversion of ascorbate to oxalate at this site and subsequently in hyperoxaluria. In addition, we showed that the intravenous administration of ascorbate to these patients and normal subjects did not increase urinary oxalate output in either group.⁶ We investigated ascorbate metabolism in three patients with enteric hyperoxaluria: Patient 1, a 57-year-old man in whom 82 cm of ileum was resected and right hemicolectomy performed; Patient 2, a 52-year-old woman in whom 30 cm of jejunum and 50 cm of terminal ileum remained after resection; and Patient 3, a 30-year-old man in whom 68 cm of jejunum was anastomosed to the left colon during bowel resection. All patients had a 5- to 10-fold increase in fecal fat excretion and multiple episodes of renal colic, with an average of three attacks per year, and required renal surgery two to four years after bowel resection.

The 24-hour urinary ascorbate concentrations of these patients, though low, were within the reference range (>0.2 mmol per day). Each was given 2 g of oral ascorbate as a loading dose, and 24-hour urinary ascorbate and oxalate excretion was monitored as described previously.⁶ The patients had significant (P = 0.05, Mann–Whitney nonparametric statistics) hypoexcretion of ascorbate (excretion expressed as a percentage of the loading dose: 6.4 percent in Patient 1, 6.1 percent in Patient 2, 0.4 percent in Patient 3; 19.9 to 29.3 percent in four normal subjects) and hyperexcretion of oxalate (2.35 percent, 0.74 percent, 1.35 percent, and 0.37 to 0.5 percent, respectively). The ascorbate-induced hyperoxaluria in our patients may partly explain why renal oxalate excretion in such patients is not stabilized by a low-oxalate diet.^{7,8} Treatment with high-dose calcium (3 g per day) and a low-fat diet normalized renal oxalate excretion in all three of our patients (<0.50 mmol per day; range before treatment, 0.92 to 1.07). Urinary calcium excretion after several days of high-dose calcium loading was less than 5 mmol per day (normal, <7.5). The biochemical changes have been paralleled by a marked reduction in stone formation in all three patients. Although oxalate excretion was controlled by high-dose calcium supplements, it is recommended that patients with hyperoxaluria, like those with recurrent calcium-stone formation, not receive high-dose ascorbate supplements.⁶

	JENNIFER M. BROWN, M.B.CH.B.
	AINSLEY H. CHALMERS, PH.D.
	DAVID M. COWLEY, M.B.CH.B.
South Brisbane 4101,	BRETT C. MCWHINNEY, B.Sc.
Australia	Mater Misericordiae Public Hospitals

- Deren JJ, Porush JG, Levitt MF, Khilnani MT. Nephrolithiasis as a complication of ulcerative colitis and regional enteritis. Ann Intern Med 1962; 56:843-53.
- Dowling RH, Rose GA, Sutor DJ. Hyperoxaluria and renal calculi in ileal disease. Lancet 1971; 1:1103-6.
- Smith LH, Fromm H, Hofmann AF. Acquired hyperoxaluria, nephrolithiasis, and intestinal disease: description of a syndrome. N Engl J Med 1972; 286:1371-5.
- Earnest DL, Johnson G, Williams HE, Admirand WH. Hyperoxaluria in patients with ileal resection: an abnormality in dietary oxalate absorption. Gastroenterology 1974; 66:1114-22.
- Dobbins JW, Binder HJ. Effect of bile salts and fatty acids on the colonic absorption of oxalate. Gastroenterology 1976; 70:1096-100.
- Chalmers AH, Cowley DM, Brown JM. A possible etiological role for ascorbate in calculi formation. Clin Chem 1986; 32:333-6.
- Hofmann AF, Laker MF, Dharmsathaphorn K, Sherr HP, Lorenzo D. Complex pathogenesis of hyperoxaluria after jejunoileal bypass surgery: oxalogenic substances in diet contribute to urinary oxalate. Gastroenterology 1983; 84:293-300.
- Barilla DE, Notz C, Kennedy D, Pak CYC. Renal oxalate excretion following oral oxalate loads in patients with ileal disease and with renal and absorptive hypercalciurias: effect of calcium and magnesium. Am J Med 1978; 64:579-85.

SCIENCE OR SCAM?

To the Editor: Doctors throughout the United States are being approached to join the Clinical Advisory Board of a company called United Sciences of America. Here is an overview of its activities.

United Sciences is a multilevel marketing operation similar to that of Shaklee, Amway, and Herbalife. Distributors (called "independent associates") are recruited with a high-technology videotape that suggests that the company's products can help protect against heart disease and cancer. Independent associates are urged to use the products themselves and to persuade others to become independent associates; these, in turn, use the products and recruit more independent associates. When sales volume is sufficient, those near the top of the heap receive a percentage of the sales of those below them.

Anyone can become an independent associate by completing an application and paying \$24.50 for a "Success System Kit" and manual. More than 100,000 have done so since January of this year, when the company began public operations. No knowledge of nutrition or medical care is required. According to the manual, United Sciences' nutritional products are "truly revolutionary" and "represent the basic elements of a highly effective program for optimal health." The manual also claims that the products constitute "the finest nutritional program ever developed" (despite the fact that no foods or dietary advice are involved). Independent associates pay \$100 for a month's supply, which retails for \$135. The company projects gross sales of \$150 million this year and says it is the fastest growing business in American history.

Independent associates are asked to submit the names of doctors

for United Sciences' Clinical Advisory Board. Hospital residents as well as office-based physicians are being solicited. When a name is received, the doctor is sent an information kit that includes the introductory videotape, a videotape about research findings, and applications to join as a research member or physician affiliate of the Clinical Advisory Board. Research members are expected to conduct research on their patients, whereas affiliates are merely placed on a mailing list for medical reports.

The applications ask how many referrals the doctor can accommodate. According to the plan, the company will refer users who have questions about United Sciences' products or who need general medical care. Some doctors have reported being asked by independent associates to sell the products to their patients or recommend that they buy them from an independent associate (with a commission to the doctor possible).

I doubt that United Sciences' products are "a highly effective program for optimal health." As far as I know, they were not tested before marketing. Moreover, an optimal health program should involve more than high-priced food supplements, protein powder, and candy bars.

Kansas City, MO 64108

JOHN H. RENNER, M.D. St. Mary's Hospital

OCCASIONAL NOTES

MARKETING A NUTRITIONAL "REVOLUTIONARY BREAKTHROUGH"

Trading on Names

The fact that they have M.D.'s backing up the product is the biggest plus they have. . . . For decades the multilevel field [of marketing] has been the province of snake-oil salesmen, so the credibility provided by top-name medical people is invaluable.

THESE quotes are from "Big Plans," published in February 1986 in *Inc.*, the "magazine for growing companies." Who are "they," what is the product, who are the M.D.s, and are they really top-name medical people?

"They" are United Sciences of America, Inc. (USA, Inc.), of Carrollton (Dallas), Texas. The "product" is a nutritional supplement — in fact, four supplements. The M.D.s backing the product are members of the Scientific Advisory Board of USA, Inc.; most of them are highly recognized in their fields of expertise, but not in nutrition.

What intrigued me about USA, Inc., was a statement from its "Company Overview" of its corporate mission: "To provide all Americans with the potential of optimum health and vital energy through state-ofthe-art nutrition." To accomplish this, "United Sciences of America, Inc., has drawn together into a single corporate entity the brilliant talents of worldrenowned scientists, medical researchers and business experts to achieve a new national goal." The statement continued,

United Sciences of America, Inc.'s revolutionary program was born out of necessity: a dedicated response to the soaring dangers to our health from toxic pollution, stressful lifestyles and the loss of vital nutrients in food from "modern" farming techniques, mass processing and improper cooking.

From the NEJM Archive. Copyright © 2009 Massachusetts Medical Society. All rights reserved.

The New England Journal of Medicine Downloaded from nejm.org at UQ Library on April 2, 2017. For personal use only. No other uses without permission.